This study encompassed seven cases of patients who underwent a transformation from EGFR-mutant non-small cell lung cancer (NSCLC) after receiving various TKIs (Gefitinib, Afatinib, Erlotinib, or Osimertinib), ultimately transitioning to small cell lung cancer (SCLC). Here, EGFR is linked to non-small cell lung carcinoma.